injections using a needleless technique, which may increase staff and patient safety 5 .
The addition of oxycodone as an option for subcutaneous opioid administration may offer several advantages. First, although oxycodone has renally-excreted active metabolites, they are not thought to play a significant role in either the analgesic effect or side-effects associated with oxycodone 2 . It is therefore an appropriate choice of opioid (as is fentanyl, which has no active meta-bolites) in patients with renal impairment 2 . Morphine is commonly avoided in such patients because of the risk of accumulation of metabolites, in particular morphine-6-glucuronide, which is also excreted by the kidneys and is a more potent mu-opioid agonist than morphine 2 . Second, use of oxycodone avoids the problem of the large and potentially painful injection volume (up to 3 to 4 ml) that might be needed for subcutaneous fentanyl.
Administration of an opioid other than fentanyl by subcutaneous injection may therefore be a reasonable treatment option in some critically ill patients. However, the pharmacokinetic characteristics of oxycodone administered as a subcutaneous bolus dose in either critically ill or healthy populations have not been previously published.
The absence of pharmacokinetic data for subcutaneous oxycodone means that clinicians are poorly equipped to prescribe subcutaneous oxycodone as a safe and effective alternative opioid analgesic for patients who are unable to tolerate morphine, or in those patients with renal impairment where avoidance of morphine is thought to be desirable. To facilitate the rapid titration of analgesia while minimising the risk of adverse effects, the optimal frequency and dose of intermittent subcutaneous injections must be established, which requires determination of the rate of absorption, the time to peak blood concentration and the rate of elimination of oxycodone.
The pharmacokinetics of subcutaneous morphine in healthy volunteers have been studied previously and a large variation in morphine blood concentrations found 6 . It is therefore important to quantify the degree of variation with oxycodone and to look at any differences in absorption kinetics between healthy subjects and critically ill patients. Should differences exist, it would mean that treatment regimens based on data from healthy subjects may not be directly transferrable to critically ill patients.
The aim of this study was to determine and compare parameters for drug exposure (maximum concentration [C max ]) and area under curve extrapolated to infinity [AUC ∞ ]), parameters of absorption (time to maximum concentration [t max ] and mean residence time [MRT]) in critically ill patients and healthy volunteers.
MATERIALS AND METHODS

Subjects
After obtaining ethical approval from the Royal Adelaide Hospital Human Research Ethics Committee (approval numbers: patient study 71010 and healthy volunteers 71011) and written informed consent, 10 healthy male volunteers and 10 patients (eight male and two female) in the high dependency unit were enrolled in the study which was conducted in accordance with the National Health and Medical Research Council of Australia guidelines.
Healthy cohort
Healthy subjects were recruited by advertisements in the university community. Exclusion criteria included hypersensitivity or allergy to opioids, current use of opioid or psychoactive medications, current or previous alcohol or drug abuse, a positive urine drug screen for opioids, regular use of drugs or herbal medications known to induce or inhibit CYP2D6 enzymes, blood donation within the three months prior to the study (this is a general requirement of the Research Ethics Committee for all patients and healthy subjects who are having multiple blood samples taken for research purposes) and abnormal liver or kidney function.
One week before commencing the study, each participant provided a medical history and underwent physical and laboratory examinations (haematology, biochemistry including liver function, and urinalysis). The 10 participating healthy subjects were free of any acute illness. One participant had pharmacologically-controlled chronic hypertension and was later excluded from analysis (see details below). Each participant was followed up one week after the study, undergoing a repeat physical examination and laboratory investigations; any adverse events following the study were sought.
In order to antagonise any adverse pharmacodynamic effects of oxycodone, oral naltrexone was administered. The first dose of 25 mg was given 12 hours before study commencement; the second dose of 50 mg was given one hour before subcutaneous oxycodone dosing. After the completion of the study, a final dose of naltrexone (25 mg) was administered before subjects were discharged home, to minimise the potential for late adverse effects.
A urine drug screen, to exclude recent recreational drug use, was performed on the morning before oxycodone administration using a standard urine-based dipstick test DipScan (Point of Care Diagnostics Australia Pty Ltd, Artamon, NSW).
Critically ill cohort
Patients in the high dependency unit were selected for study if they required PCA fentanyl as a part of their acute pain management, already had an arterial line in situ for monitoring and clinical management and were aged between 18 and 75 years. Exclusion criteria included contraindications to the use of oxycodone or fentanyl (including a history of allergic reactions) and significant hepatic impairment (defined as liver function tests greater than three times the normal range). Acute Physiological and Chronic Health Evaluation II scores were calculated on the day of the study. One patient was given 0.5 mg of midazolam for agitation at the five hour sampling time. No other patients were given corticosteroids, antidepressants or benzodiazepines, which might have affected oxycodone metabolism.
Study design and procedures
Each healthy subject had an 18 G intravenous cannula placed in a forearm or antecubital fossa vein for blood sampling. Arterial blood samples were not collected from the healthy volunteers, given the risk of radial artery damage. Both arterial and venous blood samples were collected from the patients. A 20 ml blood sample was obtained before oxycodone administration for assay standards. Subjects were monitored with pulse oximetry, noninvasive blood pressure monitoring (healthy cohort) or invasive arterial blood pressure monitoring (critically ill patients) and infrared tympanic thermometer measurements at regular intervals. They were also observed and scored for sedation and asked about nausea and vomiting.
Each subject received a single subcutaneous bolus dose of 10 mg (healthy subjects) and 5 mg (critically ill patients) of oxycodone injected over one minute through a 27 G needle sited in the subcutaneous tissue just below the clavicle. The subcutaneous needle was primed with oxycodone prior to insertion and the bolus dose administered immediately upon insertion.
Blood samples (5 ml) were collected via the blood sampling cannulae at 2, 5, 10, 15, 30, 60, 90, 120, 180, 240, 300, 360 and 480 minutes after oxycodone dosing. Samples were stored in heparinised tubes and kept on ice before centrifugation for 10 minutes at 1500 g. Plasma separated by centrifugation was stored at -20°C until analysis.
Monitoring
Safety assessments were conducted throughout the study period. These included adverse events monitoring, vital signs (blood pressure, heart rate, temperature, pulse oximetry and respiration rate) and sedation scores. During the study period, respiratory rate, sedation scores and nausea/vomiting were recorded every 30 minutes for the first three hours, and then hourly for the duration of the study. Level of sedation was scored on a four-point scale from 0 to 3 (0=wide awake, 1=rouses easily and can stay awake; 2=rouses easily but has difficulty staying awake, and 3=somnolent, difficult to rouse) 5 . Degree of nausea and vomiting was scored on a scale from 0 to 3 (0=none, 1=mild and does not need treatment, 2=treatment was effective, 3= persists despite treatment). Peripheral oxygen saturation levels and respiratory rates were monitored and the lowest values recorded. Any other adverse events reported by the subjects were also documented.
Oxycodone assay Healthy group
Oxycodone was assayed using a high performance liquid chromatography method modified from that reported by Cheremina et al 7 . To assess the quality of the assay, seven standard curves were prepared in blank plasma (collected prior to any drug administration) over the concentration range of 5 to 200 ng/ml. The retention time for oxycodone was 15 minutes and for the internal standards, hydromorphone 7 minutes and codeine 10 minutes.
Critically ill group
Oxycodone was assayed using a sensitive and specific liquid chromatography-tandem mass spectrometry method. All calibration curves were linear up to 50 ng/ml. The lower limits of quantification for oxycodone was 0.2 ng/ml. The inter-day coefficients of variation were <7% and accuracy was >90% for all quality control samples at relevant plasma concentrations.
Non-compartmental analysis of pharmacokinetics
The data were analysed using a noncompartmental approach based on analysis of AUC ∞ . The AUC ∞ was extrapolated to time infinity by assuming an exponential decline (three to six data points) to estimate the terminal exponential rate constant (and therefore half-life). The analysis used previously validated scripts written in the R language 8 . 
Statistical analysis
Values are expressed as mean±SD or as mean (range) depending on their distribution. Demographic data were analysed using two-tailed unpaired t-tests. Pharmacokinetic data analysis used the R data analysis and statistical language (Version 2.10.1) 8 .
R is an open-source data analysis and statistical environment widely used in many disciplines including pharmacometrics.
RESULTS
The study was completed with no opioid-related side-effects reported in either group.
All 10 enrolled healthy subjects completed the study. However, data from three of these subjects were excluded from analysis because of analytical problems relating to interfering peaks in the blank plasma. The interfering peaks were not attributable to naltrexone.
Demographics
All of the remaining seven subjects in the healthy cohort were male: mean age 31 years (range 20 to 51), mean weight 82 kg (range 69 to 114). The average age of the 10 critically ill patients was 51 years (range 23 to 69), mean weight was 84 kg (range 57 to 100) and mean Acute Physiological and Chronic Health Evaluation II score was 10 (range 0 to 18). Eight of the 10 critically ill patients were male. The healthy group was younger than the critically ill group (P=0.003). There was no difference in weight between the groups. Diagnoses in the critically ill group included eight patients with trauma, one patient who was post abdominal aortic aneurysm repair and one patient with severe acute pancreatitis.
Pharmacokinetics
The mean concentration-time curves for dose corrected data are summarised in Figure 1 . There was a two-fold difference in AUC ∞ between the healthy subjects and the critically ill patients in the dose-adjusted data.
The non-compartmental pharmacokinetic analysis is summarised in Table 1 . Both C max and AUC ∞ were approximately two-fold lower in the patients compared with the healthy subjects for an equivalent dose, suggesting either reduced bioavailability or increased clearance. However, t max and MRT were not significantly different, suggesting similar absorption rates. Terminal half-life was longer in the healthy cohort. Kinetic parameters were generally less variable in patients compared with the healthy subjects.
DISCUSSION
This study documents the pharmacokinetics of oxycodone after a single subcutaneous dose. It also demonstrates a difference in the pharmacokinetics of oxycodone administered to a sample of critically ill patients compared with a sample of healthy subjects.
Oxycodone is used parenterally and orally as an alternative to morphine and other opioids for the treatment of moderate to severe acute pain. It has a clinical efficacy similar to morphine 9,10 with no significant differences in the incidence of sideeffects 10 .
The pharmacokinetic data for oral (controlledand immediate-release preparations), intramuscular, intravenous and intranasal oxycodone have been described [11] [12] [13] . The main objective in this pharmacokinetic study was therefore to characterise the plasma concentration-time course of oxycodone after injection of a single subcutaneous bolus dose in both healthy subjects and critically ill patients. Results from this study enabled drug exposure and rate of absorption of subcutaneous oxycodone to be estimated.
Pharmacokinetic analysis
A 10 mg dose was chosen for the healthy group but a 5 mg dose was chosen for the patient group. The smaller dose was thought to be safer in critically ill patients who were also receiving PCA fentanyl. As the kinetics of oxycodone are linear 14 , dose adjustment of concentrations and pharmacokinetic parameters was considered to be appropriate.
On first principles, the rate of absorption of oxycodone after subcutaneous injection would be expected to be influenced by factors such as the lipid solubility of the drug; injection parameters such as location, volume, depth, skin temperature and percentage of body fat; and tissue perfusion, which influences the rate of blood flow removing drug from the site of injection. This might be expected to translate into differences in the absorption kinetics between healthy volunteers (often used in pharmacokinetic studies) and the critically ill population with various co-morbidities. Interestingly, the data revealed that this is the case. The parameters of drug exposure, i.e. C max and AUC ∞ were two-fold lower in patients compared with healthy subjects. This could mean either lower subcutaneous bioavailability or increased clearance.
Differences in oxycodone clearance or bioavailability could explain the difference in kinetics between the healthy volunteers and the patients. By necessity, there were differences in the management of the patients and the volunteers, and the use of PCA fentanyl in the patients could be one explanation for a difference in clearance. However, while it is known that CYP3A4 is the P450 enzyme responsible for metabolism of both fentanyl and oxycodone (oxycodone is also metabolised by CYP2D6), there appears to be no information to suggest that fentanyl is an enzyme inducer or inhibitor, only a substrate. If fentanyl was simply competing with oxycodone as a substrate, it is more likely that AUC ∞ results for oxycodone would be higher in patients, when in fact they were lower. We therefore believe that the use of PCA fentanyl was unlikely to be a major contributor to the kinetic differences noted between healthy subjects and patients.
The use of naltrexone was not considered to be a major contributor to the kinetic differences noted between healthy subjects and patients as it has been shown that CYP450 enzymes are not involved in the metabolism of naltrexone 15 .
In the patient cohort the differences in arterial and venous concentrations were of interest. As noted in Table 1 , mean C max was higher for the arterial compared with venous samples. This phenomenon has been documented previously and relates to the fact that venous blood reflects the transit of oxycodone through the arm 16 . This transit produces lower and later maximum concentrations. Arterial-venous differences of basic drugs have been widely documented and can be used to make inferences about the uptake of drugs into the associated region of the body 16 .
Lower bioavailability would seem more likely since increased clearance would imply an unlikely doubling of hepatic blood flow in patients, as oxycodone has a high hepatic extraction ratio and is principally cleared by the liver. AUC ∞ is a function of dose, bioavailability and clearance. Peak concentration is a function of these factors and also subcutaneous absorption rate. However, changes in absorption rate are usually associated with changes in t max . The time of the peak venous concentrations did not differ greatly between the healthy subjects and patients, suggesting that absorption rate was similar between the two groups. We therefore believe that either differences in clearance or bioavailability are able to explain our observations, with a consideration of mechanisms favouring changes in subcutaneous bioavailability. However, further experimentation with intravenous versus subcutaneous oxycodone is required to quantify the role of bioavailability. Sampling site (arterial versus venous) did not affect analysis of the pharmacokinetic data in the critically ill patient group.
The parameters influenced by absorption, i.e. t max and MRT were not different, again implying similar absorption rates in the critically ill population compared with healthy volunteers. Interestingly, kinetic parameters were less variable in patients compared to volunteers. The terminal half-life was significantly longer in the healthy compared with the patient population. Further model-based analysis is warranted to confirm this finding and determine the mechanism for shortened half-life in critical illness.
Based on the paucity of pharmacokinetic data after subcutaneous administration of this drug, no a priori power calculation was performed, which is therefore one of the limitations of this study. Hence, between-group differences in some pharmacokinetic parameters found to be similar in this study cannot be confidently excluded. Moreover, there may be some patients groups where the time-course of drug concentrations and effect are clinically significantly different from the patients in the current studies.
Clinical implications and conclusions
Our results showed that for equivalent subcutaneous oxycodone doses, blood concentrations were two-fold lower in critically ill patients compared with healthy volunteers, but that there was no difference in the times to peak blood concentration after injection. Suggestions for dose regimens of subcutaneous oxycodone to be used in critically ill patients cannot therefore be based on regimens derived from results obtained from healthy volunteers. These results not only imply that higher doses may be required in critically ill patients, although subsequent doses should always be titrated to effect, but also that the dose intervals at which the drug can be given need not differ. This warrants further model-based analysis and experimentation.
